Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interchangeability of Rotavirus Vaccines (RV1 and RV5) in Infants
NCT02193061Phase 3Completed
- Sponsor
- National Institute of Pediatrics
- Start
- Nov 2013
- Primary completion
- Jun 2017
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of human rotavirus RIX4414 strain vaccine and rotavirus vaccine, live, oral, pentavalent in rotavirus infection (7 arms), sponsored by National Institute of Pediatrics. Primary endpoints: General Symptoms - Temperature at 5 days, Seroconversion Percentages of Anti-Rotavirus Antibodies and 1 more. Started Nov 2013; status: completed.
02
Drugs
human rotavirus RIX4414 strain vaccinerotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT02193061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193061.